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Wntδ-Catenin binds the juxtamembrane domain of E-cadherin and is known to be overexpressed in some human
tumors. However, the functions of δ-catenin in epithelial cells and carcinomas remain elusive. We found that
prostate cancer cells overexpressing δ-catenin show an increase in multi-layer growth in culture. In these
cells, δ-catenin colocalizes with E-cadherin at the plasma membrane, and the E-cadherin processing is notice-
ably elevated. E-Cadherin processing induced by δ-catenin is serum-dependent and requires MMP- and PS-1/
γ-secretase-mediated activities. A deletion mutant of δ-catenin that deprives the ability of δ-catenin to bind
E-cadherin or to recruit PS-1 to E-cadherin totally abolishes the δ-catenin-induced E-cadherin processing and
the multi-layer growth of the cells. In addition, prostate cancer cells overexpressing δ-catenin display an
elevated total β-catenin level and increase its nuclear distribution, resulting in the activation of β-catenin/
LEF-1-mediated transcription and their downstream target genes as well as androgen receptor-mediated
transcription. Indeed, human prostate tumor xenograft in nude mice, which is derived from cells overexpres-
sing δ-catenin, shows increased β-catenin nuclear localization and more rapid growth rates. Moreover, the
metastatic xenograft tumor weights positively correlate with the level of 29 kD E-cadherin fragment, and
primary human prostate tumor tissues also show elevated levels of δ-catenin expression and the
E-cadherin processing. Taken together, these results suggest that δ-catenin plays an important role in prostate
cancer progression through inducing E-cadherin processing and thereby activating β-catenin-mediated
oncogenic signals.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
δ-Catenin is a member of the p120-catenin (hereafter, p120) sub-
family of armadillo proteins and is abundantly expressed in neuronal
cells. In addition, δ-catenin is overexpressed in some cancers, includ-
ing those of prostate, breast and lung [1–3]. Both p120 and δ-catenin
are known to bind to the juxtamembrane domain regions of
E-cadherin, and p120 has been shown to regulate E-cadherin stability,
endocytosis and processing. Recently, δ-catenin accumulation in the
urine of prostate cancer patients has been reported, and it promotes
prostate cancer cell growth and tumorigenesis by altering the celllloproteinase; HGF, Hepatocyte
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rights reserved.cycle and the proﬁles of survival genes [4,5]. However, siRNA-based
genetic screening of human mammary epithelial cells identiﬁed δ-
catenin as a potential suppressor of anchorage-independent growth
[6]. Accordingly, the functions of δ-catenin in tumorigenesis require
clariﬁcation.
E-cadherin, one of the major classical cadherins involved in epithe-
lial cell–cell adhesion, is frequently absent or down-regulated in various
human epithelial cancers. E-cadherin contains an extracellular domain,
a transmembrane domain and a cytoplasmic domain. Particularly, its
cytoplasmic domain associates with β-catenin, which links actin cyto-
skeletal networks via α-catenin [7,8]. The reduction in E-cadherin
expression is correlated with malignant behavior in cancer, such as
the loss of epithelial morphology and increased invasiveness and
metastatic potential. E-cadherin down-regulation depends on either
transcriptional or post-transcriptional modiﬁcations. As an example of
transcriptional regulation, the presence of a somatic mutation or
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the expressions of speciﬁc transcriptional repressors, such as Snail,
Twist or ZEB, can also reduce E-cadherin expression [9–13]. In addition,
the post-translational regulation of E-cadherin can be achieved by
controlling its endocytosis, degradation or processing. The post-
translational regulation of E-cadherin is particularly linked with p120.
p120 promotes the cell surface trafﬁcking of cadherins, regulates cad-
herin stability and turnover at the plasma membrane [14–17], and
also facilitates the recycling of cadherin back to the cell surface [14,18].
E-cadherin processing occurs when cells are exposed to various
stimuli that activate speciﬁc proteases. For example, E-cadherin
cleavage results from the activation of presenilin-1 (PS-1)/γ-secretase,
caspase, calpain, MMP-3, MMP-7, MT1-MMP, plasmin, kallikerin 7,
ADAM10 or ADAM15, which can generate different N-terminal and
C-terminal E-cadherin fragments [19–24]. Ectodomain shedding of
E-cadherin releases soluble E-cadherin fragments, which affect
its homophilic associations [25]. Recent reports demonstrate that
ADAM15 activity causes ectodomain shedding of E-cadherin with sub-
sequent ErbB receptor activation and signaling through the Erk path-
way [26]. An E-cadherin C-terminal fragment that can enter the
nucleus and regulate p120-Kaiso-mediated signaling has also been
reported [27]. Accumulated evidence suggests that E-cadherin proces-
sing involves many proteases and affects many cellular functions,
including adhesion, proliferation, migration and invasion/metastasis,
due to E-cadherin loss- or gain-of-function. Although the presence of
tumor-speciﬁc or bacteria-induced E-cadherin fragments suggests
that the processing of E-cadherin should be tightly regulated
[21,28,29], the exact mechanisms involved have not been elucidated.
Lu et al. reported that δ-catenin binds to E-cadherin [30]. Recently
we found that δ-catenin preferentially binds to E-cadherin in epithe-
lial cells and localizes at the plasma membrane when stable cell–cell
junctions are formed [31]. However, the functions of δ-catenin in
epithelial and epithelial-derived carcinoma cells remain undeter-
mined. In the present study, we found that human prostate cancer
cells overexpressing δ-catenin show an increase in multi-layer
growth in culture and substantial processing of plasma membrane
E-cadherin. Our results suggest that δ-catenin-induced E-cadherin
processing was found to be dependent on the activities of MMP and
PS-1/γ-secretase and on extracellular serum factors. Introducing
deletion mutations on δ-catenin that deprives the ability to bind
E-cadherin or to recruit PS-1 to E-cadherin totally abolishes the
δ-catenin-induced E-cadherin processing and multi-layer growth of
the cells. Interestingly, the levels of total and nuclear β-catenin, one
of the major components of E-cadherin complex, are elevated in
cells overexpressing δ-catenin, and the expressions of their down-
stream target gene for β-catenin/LEF-1 as well as androgen
receptor-mediated transcription are increased in these cells. In accor-
dance, human prostate tumor xenograft, which is derived from cells
overexpressing δ-catenin, shows increased β-catenin nuclear locali-
zation and more rapid growth rates. Furthermore, metastatic xeno-
graft tumor weights positively correlate with the level of 29 kD E-
cadherin fragment, and primary human prostate tumor tissues also
show elevated levels of δ-catenin expression and E-cadherin proces-
sing. Our results suggest that δ-catenin plays a role in prostate cancer
progression through inducing E-cadherin processing and thereby ac-
tivating β-catenin-mediated oncogenic signals.2. Materials and methods
2.1. Plasmids and antibodies
The constructions of full length and ΔC787 δ-catenin in pEGFP-C1
have been previously described [32]. The WT and D257A mutants of
PS-1 in pCS4-HA were generated by PCR ampliﬁcation and cloned
into pCS4-HA vector.The antibodies used in the present study were as follows: anti-δ-
catenin (C98320); and E-cadherin (C20820) (BD Biosciences),
E-cadherin (#3195) (Cell signaling); anti-GFP (632376) and β-catenin
(C2206) (Sigma); anti-α-tubulin (sc5286), β-tubulin (sc5274), cyclin
D1 (sc20044), CDK4 (sc260), androgen receptor (sc7305) and
E-cadherin (sc7870) (Santa Cruz Biotech.); α-Histone H3 (05–499)
(upstate). For immunohistochemistry, anti-δ-catenin (ab54578)
(abcam) and β-catenin(#9582) (Cell Signaling Technology) were
used. HA epitope was detected using media from 12CA5 hybridoma.
2.2. Cell culture, transfection, and reagents
CWR22Rv-1 and PC3 human prostate cancer cell lines were main-
tained in RPMI and DMEM, respectively, supplemented with 10% FBS
and 1% penicillin/streptomycin at 37 °C in a 5% CO2 atmosphere. Rv/C
or Rv/δ cells were grown in G418 (Sigma) 125 μg/ml supplemented
media. Plasmid DNA was transfected using Plus/Lipofectamine re-
agent (Invitrogen), and siRNAs were transfected using Lipofectamin
RNAiMAX (Invitrogen) according to the manufacturer's instructions.
δ-Catenin siRNAs were purchased from Sigma-Aldrich : siRNA#1
(Oligo# 996742), siRNA#2 (Oligo#996743). For RT-PCR, the primer
set for cyclin D1 was 5′-gaccatccccctgacggccgag-3′/5′-ccgcacgtcggt
gggtctgc-3′, for c-myc was 5′-tctggatcaccttctgctgg-3′/5′-cctcttga
catttctcctcg-3′, for c-jun was 5′-atgactgcaaagatggaaac-3′/5′-gtcac
gttcttggggcaca-3′, and for GAPDH was 5′-atcaccatcttccaggagcga-3′/
5′-agttgtcatggatgaccttggc-3′. Synthetic testosterone, R1881, was
from NEN Life Science (Boston, MA, USA), and charcoal dextran-
treated (CDT) FBS was from Invitrogen.
2.3. Immunostaining and image acquisition
Cells growing on glass coverslips were ﬁxed with 4% PFA in PBS,
blocked using PBS containing 1% goat serum for 1 h at RT, and incu-
bated with primary antibody for 16 h at 4 °C. Cells were then washed
in PBS, incubated for 1 h at RT with Rhodamine-conjugated or Alexa
Fluor 633-conjugated secondary antibody, and washed in PBS. Cells
were visualized under an inverted ﬂuorescent microscope as previ-
ously described [31]. For confocal analyses, images were visualized
and acquired using a TCS SP5 AOBS/Tandemmicroscope (Leica Micro-
scope systems GmBh) at Korea Basic Science Institute, Gwangju
center, Republic of Korea.
2.4. Immunoblotting and immunoprecipitation
Immunoprecipitation and immunoblotting were performed as
previously described [33]. Immunoprecipitation was performed on
lysates by incubation with primary antibody for 16 h at 4 °C and im-
munoprecipitates were pulled down using protein G-Sepharose
beads (GE healthcare). All results are representative from at least
three independent experiments.
2.5. Puriﬁcation of cell surface proteins by biotinylation
Nearly conﬂuent cells in 100 mm dishes were washed and collect-
ed in 1.5 mL microcentrifuge tubes using ice-cold reaction buffer
(0.1 M phosphate, 0.15 M NaCl, pH 8.0). Cell surface proteins were
labeled with biotin by incubating tubes with 0.5 mM Sulfo-NHS-
SS-Biotin (Pierce) at RT for 30 min. Cells were then lysed in lysis buff-
er (10% glycerol, 25 mM HEPES, 150 mM NaCl, 1 mM EDTA, 25 mM
NaF, 1 mM Na3VO4, 1% NP40, 0.2 mM PMSF, and protease inhibitor
mixture) and cleared by centrifugation at 13,200 rpm for 15 min at
4°C. Equal amounts of protein lysates were then subjected to pull-
down with streptoavidin-agarose beads (Pierce), and biotinylated
plasma membrane E-cadherin was detected by immunoblotting
with an E-cadherin antibody. For lysosomal-endocytic pathway inhi-
biting experiments, cells were treated with E-64 (10 μM) at 37°C for
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For growth factor treatment experiments, cells were exposed to
serum deprivation for 8 h and further treated with none (−), FBS
(10%), HGF, insulin, or EGF at either 20 ng/ml or 40 ng/ml concentra-
tions for 16 h, prior to biotinylation. For protease inhibitor experi-
ments, cells were treated with MMP Inhibitor, GM6001 (10 μM,
BIOMOL International (EI-300)) or with γ-secretase inhibitor
(20 μM, Calbiochem (565760)) for 16 h, prior to biotinylation.
2.6. Cell fractionation
To separate cytoplasmic, nuclear andmembrane extracts, cell frac-
tionation was performed as previously described [34]. In brief, cells
were lysed in buffer A containing 15 mM HEPES (pH 7.4), 80 mM
KCl, 5 mM EDTA, 1 mM PMSF and 25 mM sucrose. Lysates were
homogenized and centrifuged at 1000×g for 10 min at 4°C. Soluble
fractions were centrifuged at 22,000 rpm for 90 min at 4°C. Superna-
tants were used as cytoplasmic fractions, and pellets containing
nuclei were resuspended in lysis buffer.
2.7. Reporter assay
TOPFLASH and pGL-ARE4-Luc have been previously described
[35,36]. To determine the hormone effects, cells were grown under
charcoal dextran-treated (CDT) FBS for 3 days before being plated.
The cells were plated into 24-well plates 1 day before transfection,
and then were transfected with 100 ng of the reporters, 1 ng of
phRL-TK. For ARE4-Luc assay, cells were treated with R1881 at indi-
cated ﬁnal concentration after 6 h. After 36 h incubation, luciferase
activity was measured with a Dual-Luciferase Reporter Assay (Pro-
mega) and normalized to Renilla luciferase. Each experiment has
been performed in triplicate.
2.8. Animal models
Animal models were established, and histological and optical ana-
lyses were performed as previously described [37]. Brieﬂy, ﬁve-to six-
week-old male BALB/c nu−/nu− mice (20–30 g body weight) were
purchased from the Shizuoka Lab Animal Center (SLC), Japan. Animal
care, experiments and euthanasia were performed in accordance with
protocols approved by the Chonnam National University Animal
Research Committee.
To generate nude mice carrying either s.c. or i.v. tumors, Rv/C or
Rv/δ cells were harvested. Cells (106) were then suspended in
100 μl of PBS and were injected s.c. into the left (Rv/C cells) and
right (Rv/δ cells) thighs of each mouse, or were injected i.v. through
a lateral tail vein using a 1-cm3 syringe. Tumor volumes (mm3)
were estimated using (L×H×W) /2 where L=length, W=width,
and H=height [38].
After euthanizing animals, tumors were obtained. Final tumor vol-
umes were measured, and frozen sections were prepared to determine
the presence of GFP-δ-catenin ﬂuorescence by ﬂuorescent microscopy.
Immunohistochemical staining for δ-catenin and β-catenin was per-
formed as previously described [39]. Remaining tumors were collected
and harvested to determine E-cadherin statuses. Organs were ﬁxed in
10% neutral buffered formalin, parafﬁn embedded, sectioned and
stained with H&E.
2.9. Human prostate cancer sample preparation
Human prostate cancer specimens were obtained from the radical
prostatectomy series at Chonnam National University Hospital. Spec-
imens were processed within 20 min of surgical resection. Alternate
sections of prostate glands were submitted for histological review,
and remaining sections were snap-frozen and stored. Clinical and
pathologic data were acquired after obtaining approval from theInstitutional Review Board (IRB) at Chonnam National University
and were managed on a secure relational database. All samples
were trimmed to ensure that >95% of the sample represented lesions.
3. Results
3.1. CWR22Rv-1 cells overexpressing δ-catenin display increased
multi-layer cluster formation
Establishment of polyclonal CWR22Rv-1 stable cell line overex-
pressing mouse δ-catenin cDNA with EGFP and characterization of in-
creased cell growth property in this cell line were previously
described [5]. In this initial observation, δ-catenin overexpressing
cells tended to form clusters and show disrupted E-cadherin distribu-
tion. To further demonstrate this, we reexamined the extent of multi-
layer cluster formation of CWR22Rv-1 overexpressing δ-catenin
(Rv/δ) compared with mock expressing CWR22Rv-1 cells (Rv/C).
Rv/C cells express a moderate amount of endogenous δ-catenin
(right panel, Fig. 1A), and the extent of exogenous GFP-δ-catenin ex-
pression level in Rv/δ is similar to that of exogenous GFP level in Rv/C
(Left panel, Fig. 1A). Microscopic observations showed clear cluster
formation and multi-layer growth pattern of Rv/δ cells while Rv/C
cells grewwith monolayer morphology (Fig. 1B). Z–X and Z–Y section
analyses using confocal microscope revealed that this cluster has an
average height of 100 μm, on which ﬁve or six cells are stacked
(data not shown), and δ-catenin localization in this multi-layer
cluster is mainly at the cell–cell interfaces (Fig. 1C). Immunoﬂuores-
cent staining of E-cadherin showed that colocalization of δ-catenin
with E-cadherin at the cell–cell interfaces is observed in the majority
of the cells. However, it was also observed that there is an inverse
correlation between δ-catenin and E-cadherin levels in some kinds of
cells. That is, cells with weak immunoreactivity of E-cadherin have
strong δ-catenin expression (arrow, Fig. 1D), while cells with no
detectable δ-catenin show high cell–cell interface distribution of
E-cadherin (arrowhead, Fig. 1D). To support this, Rv/δ cells were inde-
pendently immunostained with monoclonal E-cadherin antibody and
larger image was obtained (upper panel, Fig. 1E). Pixel intensity ana-
lyses revealed that there are three types of cell–cell junction in Rv/δ
cells; ROI type 1 represents the junction that δ-catenin and
E-cadherin co-localizes with high intensity while ROI type 2 and type
3 represent the junctions which showed inverse correlation between
δ-catenin and E-cadherin levels (bottom panel, Fig. 1E). Quantitative
analyses of each cell–cell junction showed relative ratio of each type
of ROIs (n=209, Fig. 1F). These results suggest that δ-catenin may
act as a negative regulator for plasma membrane E-cadherin at the
cell junction.
3.2. E-cadherin processing is promoted by δ-catenin
In order to explore the E-cadherin status after δ-catenin overex-
pression, E-cadherin from whole cell lysates of Rv/C and Rv/δ was
analyzed. As a result, a remarkably elevated level of fragmented
E-cadherin band was detected in Rv/δ cell lysates compared to that
in Rv/C cells, and a concomitant decrease of full-length E-cadherin
was also observed (Fig. 2A). Quantitative densitometric evaluation
for full-length E-cadherin revealed that approximately 5% of full
length E-cadherin is decreased in Rv/δ cell lysates, indicating that
only a part of the E-cadherin is projected to be processed in
δ-catenin overexpressing CWR22Rv-1 cells. A similar pattern of the
processed E-cadherin fragment was also observed in PC3 cells when
δ-catenin was transiently overexpressed (Fig. 2B), and the same pat-
tern was also observed with δ-catenin without GFP tag, ruling out the
possibility of GFP tagging effect (Supplemental Fig. 1). Knock-down of
δ-catenin using two different speciﬁc siRNAs against δ-catenin in Rv/δ
cells blocked the whole E-cadherin processing in a dose dependent
manner (Fig. 2C), suggesting that this E-cadherin processing is
Fig. 1. δ-Catenin overexpression induces increased multi-layer growth in CWR22Rv-1 cells. (A) Establishment of stable polyclonal CWR22Rv-1 cells overexpressing GFP (Rv/C) or
GFP-δ-catenin (Rv/δ). Expression level of exogenous GFP epitope (left panel) and δ-catenin (right panel) were shown. Rv/C cells harbor only lower levels of endogenous δ-catenin
while Rv/δ cells have robust exogenous δ-catenin.(B) Multi-layer cluster formation of Rv/δ cells. Cell growth morphologies of Rv/C and Rv/δ in culture were observed by phase con-
trast microscopy. High magniﬁcation images of multi-layer cluster region in boxed area were shown in right panel.(C) Membrane localization of δ-catenin in Rv/δ cells. GFP signal
from Rv/δ cells was observed under confocal ﬂuorescent microscopy. Z–X and Z–Y section analysis of multi-layer clusters revealed that on average ﬁve to six cells were stacked at a
height of ~100 μm. High magniﬁcation image was shown in the bottom left panel.(D–F) Immunoreactivity of membrane E-cadherin in Rv/δ cells. Paraformaldehyde-ﬁxed and Tri-
ton X-100-permeabilized Rv/δ cells were incubated with E-cadherin (BD) antibody and subsequently with Rhodamine-conjugated mouse secondary antibody. While the majority of
cells showed co-localization of δ-catenin with E-cadherin, some sort of cells showed an inverse correlation between δ-catenin and E-cadherin level. The arrow and the arrowhead in
the bottom left panel indicate representative cell that showed high δ-catenin level with low E-cadherin immunoreactivity, and low δ-catenin level with high E-cadherin immuno-
reactivity, respectively (D). Rv/δ cells were independently immunostained with monoclonal E-cadherin antibody (Cell Signaling Technology, epitope: sequence surrounding 780th
amino acid of human E-cadherin) and Alexa Fluor 633 goat anti-mouse IgG (H+L) secondary antibody. Representative image was shown (upper panel, E). There are three types of
junction being classiﬁed according to relative levels of δ-catenin and E-cadherin. ROI type 1 represents the junctions that δ-catenin and E-cadherin co-localizes with high intensity
while ROI type 2 and type 3 represent the junctions which showed inverse correlation between δ-catenin and E-cadherin level (bottom panel, E). Red, E-cadherin; Green, GFP-δ-
catenin. Quantitative numbers of each type of junction were shown (F). Note that δ-catenin and E-cadherin co-localized mainly at the cell–cell junction, while intracellularly,
their location seems distinctive; δ-catenin localized only in a cytoplasm but E-cadherin was in both nuclear and cytoplasm. No signiﬁcant co-localization of δ-catenin and
E-cadherin was observed in intracellular region. Bar, 25 μm.
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Fig. 2. δ-Catenin overexpression promotes E-cadherin processing. (A) Enhanced E-cadherin processing in Rv/δ cells. E-Cadherin from whole cell lysates of Rv/C and Rv/δ cells were
probed with an anti-E-cadherin (BD) antibody. Shorter exposure image in the upper right panel shows a concomitant reduction of full-length E-cadherin.(B) E-Cadherin processing
in PC3 cells overexpressing δ-catenin. PC3 cells were transiently transfected with expression plasmid of δ-catenin with GFP tagging and harvested after 48 h incubation. Whole cell
lysates were subjected to Western blot.(C) Reduction of E-cadherin processing in Rv/δ cells by knock-down of δ-catenin using δ-catenin siRNA in a dose dependent manner. Cells
were transfected with two different δ-catenin-speciﬁc siRNAs, and whole cell lysates were subjected to Western blot. Shorter exposure image was shown in the upper right
panel.(D) Detection of E-cadherin processing in membrane fraction of Rv/δ cells. Rv/δ cells were fractionated into cytoplasmic (C), nuclear (N) and membrane (M). β-Tubulin
was used to exclude contamination between nuclear and cytoplasmic fractions. Shorter exposure image was shown in right panel.(E) Detection of plasma membrane
E-cadherin by biotin-labeling puriﬁcation using sulfo-NHS-SS-biotin. Puriﬁed membrane E-cadherin was probed using E-cadherin antibody either purchased from BD Biosciences
(epitope: 773–791 of E-cadherin cytoplasmic region, left panel) or Santa Cruz Biotechnology (epitope: 600–707 of E-cadherin extracellular region, right panel). Shorter exposure
image was shown in the right panel. Note that more evident patterns of E-cadherin processing were observed after puriﬁcation, and that due to the different binding epitope of each
antibody, the size and pattern of detected E-cadherin bands were different. Rv/C cells also underwent E-cadherin processing that was further potentiated in Rv/δ cells.(F) Blockage
of endocytosis increases E-cadherin processing. Cells were treated with E-64 (lysosomal protease inhibitor) for 24 h or sucrose (endocytosis blocker) for 2 h prior to harvest,
followed by biotin-labeling puriﬁcation of membrane proteins.
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induced E-cadherin processing occurs, subcellular fractionation of
the cell lysates was performed. The result shows that majority of
the processed E-cadherin fragments retains in membrane portion of
the fraction (Fig. 2D). Interestingly, E-cadherin band of approximately
29 kD was detected in the nuclear portion, suggesting that this frag-
ment may confer a putative oncogenic signal from the outside and
into the nucleus. In order to conﬁrm whether E-cadherin processing
occurs speciﬁcally at the plasma membrane, cells were labeled with
Sulfo-NHS-SS-Biotin to purify plasma membrane proteins. The
bound E-cadherin was analyzed using two different E-cadherin
antibodies with different binding epitopes (BD, which were
purchased from BD Bioscience, epitope: 773–791 of E-cadherin cyto-
plasmic region, left panel of Fig. 2E; SC, purchased from Santa Cruz
Biotech., epitope: 600–707 of E-cadherin extracellular region, right
panel of Fig. 2E). Speciﬁc puriﬁcation with biotin-labeling of plasma
membrane E-cadherin was conﬁrmed (Supplemental Fig. 2), and amore evident pattern of the E-cadherin processing was observed
after puriﬁcation. From Fig. 2E, one can see that Rv/C cells also under-
go E-cadherin processing to some extent and that this E-cadherin
processing is further potentiated by δ-catenin. When BD E-cadherin
antibody was used, E-cadherin fragments of 105, 90, 79, 62, 48 and
29 kD were detected. On the other hand, when SC E-cadherin
antibody was used, E-cadherin fragments of 96, 80, 62 and 48 kD
were detected, indicating that cleavage of E-cadherin during
δ-catenin-induced processing occurs at the extracellular domain or
the transmembrane domain of E-cadherin, which likely resembles
E-cadherin shedding by matrix metalloproteinase (MMP) or γ-
secretase. Putative cleavage sites for E-cadherin processing based on
the size of fragment and their epitope are depicted and summarized
in Table 1. As p120 is known to affect E-cadherin stability through
the endocytic pathway, we sought to determine whether the
δ-catenin-induced E-cadherin processing alternatively involved the
endocytic membrane trafﬁcking. We applied sucrose (endocytosis
Table 1
A summary of E-cadherin processing in Rv/δ cells and human prostate carcinoma tissues. Cleavage sites were estimated using the size of processed E-cadherin fragments
and epitope for each E-cadherin antibody.
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Treatment with E-64 did not alter E-cadherin processing, but sucrose
increased E-cadherin processing and especially resulted in 62, 48 and
29 kD band formations (Fig. 2F). This result strongly indicates
again that E-cadherin processing in Rv/δ cells occurred at the plasma
membrane but did not involve the endosomal–lysosomal pathway.3.3. δ-Catenin-induced E-cadherin processing depends on serum
factor(s) and requires MMP- and PS-1/γ-secretase-mediated activities
To identify the factors that affect E-cadherin processing in Rv/δ
cells, we examined the effects of several extracellular factors, includ-
ing serum (FBS) and several growth factors. When Rv/δ cells were
cultured in medium supplemented with 10% FBS, there was obviously
more E-cadherin processing than in the cells that were cultured in
serum-free medium (Fig. 3A, Supplemental Fig. 3). In order to specify
the factor(s) affecting E-cadherin processing in serum, we tested the
effects of hepatocyte growth factor (HGF), insulin, and epidermal
growth factor (EGF) on E-cadherin processing in Rv/δ cells under
serum starvation conditions. Unfortunately, none of those growth
factors promote E-cadherin processing (Fig. 3A), suggesting that
E-cadherin processing in Rv/δ cells is promoted by other currently
unknown serum factor(s). Although we were unable to identify the
speciﬁc serum factor(s) responsible for promoting E-cadherin proces-
sing, we decided to exhaust serum effects by incubating Rv/δ cells in
the same culture without medium change and then examining
E-cadherin processing. As shown in Fig. 3B, E-cadherin processing is
dramatically decreased with culture time, and this reduction cannot
be attributed to cell density changes. Thus, as both serum-free condi-
tion and exhausting serum effect by incubating Rv/δ cells in the same
culture without medium change dramatically decreased the
E-cadherin processing, it is supposed that serum factor(s) itself
would promote E-cadherin processing. However, we cannot rule out
the possibilities that some other factor(s) may also affect the proces-
sing of E-cadherin.Several studies have suggested that MMP, PS-1/γ-secretase and
caspase can induce E-cadherin processing. Because δ-catenin was
ﬁrst cloned based on its ability to bind PS-1, and because both
proteins are known to bind similar regions of E-cadherin, we
hypothesized that δ-catenin recruits and/or activates MMP and/or
PS-1/γ-secretase complexes and thus affects E-cadherin processing.
Our preliminary gelatin zymography data revealed changes in MMP
proﬁles in tumor xenograft samples obtained by injecting Rv/δ cells
into nude mice (Kim et al., unpublished data). Indeed, treatment of
CWR22Rv-1 cells with GM6001 (an MMP inhibitor) decreases the
level of 48 kD E-cadherin fragment, whereas treatment with
γ-secretase inhibitor decreases the levels of whole E-cadherin frag-
ments, except a 29 kD fragment (Fig. 3C). Interestingly, the level of
this 29 kD fragment is remarkably increased by treatments with
either MMP or γ-secretase inhibitors, indicating that production of
this fragment is inversely correlated with MMP or γ-secretase activi-
ty. To conﬁrm that E-cadherin processing by δ-catenin is promoted by
PS-1/γ-secretase activity, wild type or dominant negative mutant
(D257A) PS-1 was overexpressed in Rv/C cells and the E-cadherin
processing pattern was analyzed. As expected, overexpression of
wild type PS-1 increased levels of the 105, 90, 79, 62 and 48 kD
E-cadherin fragments, whereas expression of the PS-1 D257A did
not (Fig. 3D). Taken together, all of this suggests that δ-catenin
directly recruits and/or indirectly activates MMP or PS-1/γ-secretase
complexes to promote E-cadherin processing when extracellular
factor(s) turns this signaling cascade on.
3.4. δ-Catenin deletion mutant lacking ability to bind E-cadherin or to
recruit PS-1 to E-cadherin shows neither E-cadherin processing nor
multi-layer growth pattern
In order to conﬁrm whether δ-catenin recruitment of PS-1/γ-
secretase to E-cadherin is crucial for promoting E-cadherin proces-
sing, we used a δ-catenin deletion mutant (ΔC787 — C-terminal 787
aa deleted), which lacks the ability to bind PS-1 and to bridge
E-cadherin toward PS-1. The stable expression of δ-catenin mutant
Fig. 3. E-Cadherin processing induced by δ-catenin is serum-dependent and requires MMP- and PS-1/γ-secretase-mediated activities. (A) Effects of several growth factors on
E-cadherin processing in Rv/δ cells. Rv/δ cells were exposed to serum deprivation for 8 h and then further treated with FBS (10%), HGF, insulin or EGF at either 20 ng/ml or
40 ng/ml concentrations for 16 h, and then followed by biotin-labeling puriﬁcation of membrane proteins. Shorter exposure image was shown in the upper right panel. HGF, he-
patocyte growth factor; EGF, epidermal growth factor.(B) Effects of exhausting culture media of extracellular serum factor(s) on E-cadherin processing in Rv/δ cells. Rv/δ cells were
cultured in the same culture medium for up to 4 days, followed by biotin-labeling puriﬁcation of membrane proteins. Shorter exposure image was shown in the upper right panel.
(C) Effects of MMP (GM6001) and γ-secretase inhibitors on E-cadherin processing in Rv/δ cells. Cells were treated with either GM6001 (10 μM) or γ-secretase inhibitor (20 μM) for
16 h, followed by biotin-labeling puriﬁcation of membrane proteins. Shorter exposure image was shown in the upper right panel. (D) Effects of wild-type or D257A mutant (dom-
inant negative form) of presenilin-1 on E-cadherin processing. Rv/C cells were transfected with either WT or D257A mutant of presenilin-1 (PS-1), and then followed by biotin-
labeling puriﬁcation of membrane proteins. The bottom panel shows expression of transfected presenilin-1. Non-speciﬁc background of HA antibody was overlapped with
presenilin-1 band.
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localization of this mutant was found to be diffusely in the cytoplasm
rather than the plasma membrane, implicating the lack of plasma
membrane E-cadherin interaction (Fig. 4B). Lack of an interaction be-
tween the ΔC787 mutant δ-catenin and E-cadherin is shown by im-
munoprecipitation (Fig. 4C); thus, ΔC787 δ-catenin fails to recruit
PS-1 to E-cadherin (Fig. 4D). As expected, the E-cadherin processing
induced by full length δ-catenin is totally abolished in Rv/Δ cells
(Fig. 4E). Furthermore, it is interesting to ﬁnd that Rv/Δ cells show
mono-layer growth morphology, which strongly suggests that
δ-catenin activity to induce E-cadherin processing is prerequisite for
multi-layer cluster formation (Fig. 4F).
3.5. δ-Catenin promotes β-catenin nuclear localization and activates its
downstream target genes, including androgen receptor-mediated
transcription
β-Catenin, a major downstream effector for Wnt signaling path-
way, is involved in cell adhesion at the membrane, where it associates
with E-cadherin, α-catenin and others [40]. Because δ-catenin
overexpression alters the levels of full length E-cadherin and of
E-cadherin processing, we examined the changes in nuclear/cytoplasmic distribution of β-catenin. Interestingly, distribution
ratio of nuclear β-catenin is remarkably higher in Rv/δ cells compared
to that of Rv/C cells, while a moderately increased level of total β-
catenin is observed (Fig. 5A). These results implicate that δ-catenin
is able to regulate the size of the β-catenin pool through the E-
cadherin processing that is induced by δ-catenin overexpression.
Indeed, suppression of δ-catenin expression reverses not only E-
cadherin processing (Fig. 2C), but also the increased level of β-
catenin (Fig. 5B). In order to determine whether this altered β-
catenin distribution correlates with its β-catenin/LEF-1-mediated
downstream target gene activation, basal TOPFLASH activity was
measured in each CWR22Rv-1 cell harboring either mock, full length
δ-catenin, or ΔC787 mutant δ-catenin. TOPFLASH activity is signiﬁ-
cantly high in Rv/δ cells (Fig. 5C), and upregulation of downstream
target genes for β-catenin, such as cyclin D1, c-myc but not c-jun,
were also observed by either RT-PCR (Fig. 5D) or Western blot
(Fig. 5E). As β-catenin is known to act as an activator of androgen re-
ceptor (AR) in prostate cancer [41,42], we hypothesized that altered
β-catenin distribution by δ-catenin overexpression may affect tran-
scriptional activity of AR in response to androgen. To demonstrate
this, ARE4-luciferase activity was measured in Rv/C and Rv/δ cells
after treatment of R1881, a synthetic androgen using synthetic
Fig. 4. δ-Catenin deletion mutant lacking ability to bind E-cadherin or to recruit PS-1 to E-cadherin shows neither E-cadherin processing nor multi-layer growth pattern. (A) Establish-
ment of polyclonal CWR22Rv-1 cells (Rv/Δ) harboringΔC787 δ-cateninmutant lacking the C-terminal 787 amino acids. Expression level of GFP epitope in Rv/C, Rv/δ and Rv/Δ cells were
shown using GFP antibody.(B) Loss of membrane localization ofΔC787 δ-cateninmutant in Rv/Δ cells. GFP signal from Rv/Δ cells were observed under ﬂuorescent microscopy. Note that
ΔC787 δ-catenin mutant is mainly localized at the cytoplasm.(C) ΔC787 δ-catenin mutant lacks binding to E-cadherin. Whole cell lysates were subjected to immunoprecipitation with
GFP antibody and bound E-cadherin was probed by E-cadherin (upper panel). Levels of δ-catenin and E-cadherin in lysates were shown in the bottom panel. Arrowhead, GFP or GFP-
tagged δ-catenin; arrow, E-cadherin.(D) ΔC787 δ-catenin mutant unable to recruit PS-1 to E-cadherin. Rv cell lines were transfected with HA-presenilin-1, and whole cell lysates were
subjected to immunoprecipitation with HA antibody followed by immunoblotting with E-cadherin antibody for bound E-cadherin. Faint level of bound E-cadherin was observed due to
the endogenous δ-catenin in both Rv/C and Rv/Δ cells. Evident recruitment of presenilin-1 to E-cadherin was seen only in Rv/δ cells, which harbor full-length δ-catenin. Arrow,
E-cadherin.(E) Loss of E-cadherin processing in Rv/Δ cells. Plasma membrane E-cadherin processing was measured by biotin-labeling puriﬁcation using sulfo-NHS-SS-biotin. Shorter
exposure image was shown in the upper right panel, respectively.(F) Loss of multi-layer cluster formation of Rv/Δ cells. Cell growth morphology of Rv/Δ cells in culture was observed
by phase contrast microscopy. High magniﬁcation images were shown in the bottom panel. Bar, 25 μm.
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result, dramatically high responsiveness of AR transcription by synthet-
ic androgen was observed in Rv/δ cells compared to that of Rv/C cells
(Fig. 5F), while the level of androgen receptor itself remained quite
constant (Fig. 5G). Taken together, these results suggest that
δ-catenin overexpression activates β-catenin signaling via increased
E-cadherin processing and promotes downstream target gene activa-
tion for both β-catenin/LEF- and/or β-catenin/AR-mediated signal
transduction cascade.
3.6. δ-Catenin promotes prostate cancer progression in vivo
In order to test whether δ-catenin overexpression promotes pros-
tate cancer progression in vivo, we injected Rv/C and Rv/δ cells into
BALB/c nude mice either subcutaneously or intravenously and
obtained tumor xenograft samples as described in Materials and
Methods. When subcutaneously injecting Rv/C and Rv/δ cells into
BALB/c nude mice, the resulting tumor weight was approximately
1.8 fold larger and grew faster than those produced by control Rv/C
cells (n=4). This is in agreement with the recently published
ﬁndings of Zeng et al. [5] (Fig. 6A). However, when injecting intrave-
nously, metastasis frequencies were increased; even so, this is
statistically insigniﬁcant (Rv/C, metastatic tumor formed in one out
of ﬁve mice; Rv/δ, two out of ﬁve mice). Similarly, when we analyzed
four prostate cancer cell lines with different metastatic potential
(CWR22Rv-1, DU145, PC3, LNCaP), we found no correlation between
metastatic potential and δ-catenin overexpression [43]. When cells
were injected intravenously through a tail vein, they tended to form
skin tumors and metastasize to different internal organs, including
brain, lung and kidneys, to different extents (Kim et al., unpublished
data). Although we were unable to ﬁnd a difference between these
skin tumors in terms of weight, we made several interestingobservations regarding the tumor samples: larger tumors tended to
have more processed E-cadherin fragments, and the bands most obvi-
ously increased in larger tumors were the 80 and 29 kD E-cadherin
bands, which were detected using anti-E-cadherin antibody in SC
and BD, respectively. As shown in Fig. 6B, the highest R2 value was
obtained for the relation between the tumor weight and the density
of the 29 kD E-cadherin band. Interestingly, in these xenograft tissues,
β-catenin nuclear localization was clearly and frequently observed in
those derived from Rv/δ cells (Fig. 6C).
3.7. Increased δ-catenin expression, E-cadherin processing in human
prostate cancer specimens
In order to determine whether E-cadherin processing is increased
in primary human prostate cancer tissues and whether any correla-
tion exists between E-cadherin processing and δ-catenin level, we an-
alyzed human prostate cancer specimens with matching adjacent
normal prostate tissues. In all cases, E-cadherin processing was mark-
edly higher in the tumor, and two E-cadherin bands near the 75 kD
band detected by the SC E-cadherin antibody were most signiﬁcantly
increased in all tumors, and this band likely corresponds to 80 kD
band from cultured Rv/δ cells (Fig. 7 and Table 1). With the exception
of patient #4, the upper 75 kD E-cadherin band (Arrow in Fig. 7) was
observed only in lysates from tumor tissues. This exception may have
originated from hyperplastic transition. Marked overexpression of
δ-catenin was found in two out of ﬁve tumor samples, and slightly
increased expression was found in the rest two samples.
4. Discussion
δ-Catenin was originally identiﬁed as a molecule that interacts
with presenilin (PS-1), and its abundant expression in the brain
Fig. 5. δ-Catenin overexpression alters subcellular β-catenin distribution and activates its downstream effectors. (A) Increased β-catenin nuclear localization in Rv/δ cells. Nuclear
and cytoplasmic fractionation of β-catenin was performed in Rv/C and Rv/δ cells. Moderate increase in total β-catenin level was also observed in Rv/δ cells. α-Tubulin was used as a
cytoplasmic marker and α-histone H3 was used as a nuclear marker.(B) Knock-down of δ-catenin from Rv/δ cells reverts increased β-catenin level into that of Rv/C cells. Cells were
transfected with either control or δ-catenin-speciﬁc siRNA, and the level of β-catenin was measured fromwhole cell lysates after 48 h incubation.(C) Increased TOPFLASH activity in
Rv/δ cells. Cells were transfected with LEF-1 together with TOPFLASH reporter plasmid, and luciferase activity was measured after 48 h incubation. *, pb0.001 compared to TOP-
FLASH in Rv/C.(D and E) Augmentation of β-catenin target gene level in Rv/δ cells. Levels of several target genes for β-catenin/LEF-1 were analyzed by RT-PCR (D) and Western
blot (E) in Rv/C and Rv/δ cells. GAPDH, cyclin-dependent kinase 4 (CDK4), and α-histone H3 were used as loading controls.(F) Greater androgen-stimulated androgen receptor
(AR) activation in Rv/δ cells. Cells were transfected with pGL-ARE4-luc, and R1881 was treated 24 h post-transfection. After additional 24 h incubation, luciferase activity was mea-
sured. Each bar represents the mean±S.D. In these lysates, the levels of endogenous androgen receptor in Rv/C and Rv/δ cells were shown (panel G). No signiﬁcant induction was
observed.
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genesis. However, recent discoveries, including its overexpression in
several carcinomas and its ability to interact with E-cadherin, suggest
that δ-catenin plays roles in epithelial cells and carcinomas. In this
study, we found that prostate cancer cell lines overexpressing
δ-catenin display noticeable multi-layer growth, E-cadherin proces-
sing and nuclear β-catenin localization. δ-Catenin may promote
prostate cancer progression through the activation of downstream
signal cascade for β-catenin/LEF-1- or β-catenin/AR-mediated
transcription.
E-Cadherin cleavage can result from the activation of PS-1/γ-
secretase, caspase, MMP7 or Metrilysin, calpain, or ADAM10
[19–24]. Because δ-catenin can interact with both PS-1 and
E-cadherin and PS-1/γ-secretase can cleave E-cadherin, we ques-
tioned whether the cleavage of E-cadherin by PS-1/γ-secretase is me-
diated by δ-catenin or whether it is competitively inhibited. In the
present study, overexpressed δ-catenin increases the cleavage of E-
cadherin. The cleavage of E-cadherin by δ-catenin is found to be pro-
moted by unidentiﬁed serum factor(s) (not HGF, insulin or EGF) and
mediated by MMP(s) and PS-1/γ-secretase, the latter of which con-
curs with the ﬁndings of Marambaud et al. [44], though our ﬁndings
differ with respect to the sizes of the E-cadherin fragments produced.
In previous studies, staurosporin treatment, which induces apoptosis,led to three E-cadherin C-terminal fragments, namely E-Cad/CTF1
(38 kD), E-Cad/CTF2 (33 kD), and E-Cad/CTF3 (29 kD) in A431 cells.
MMP, PS-1/γ-secretase, and caspase-3, respectively, were found to
be responsible for the production of these fragments. In the present
study, treatment with GM6001 (an MMP inhibitor) decreased the
levels of 48 kD E-cadherin fragment, suggesting that anMMP is respon-
sible for the production of the 48 kD E-cadherin fragment (Table 1 and
Fig. 8), which resembles the formation of a E-Cad/CTF1 (38 kD) frag-
ment described by Marambaud et al. [44]. One discrepancy between
our ﬁndings and those of Marambaud et al. [44] concerns the size of
PS-1/γ-secretase-mediated E-cadherin fragment(s). In contrast to
their E-Cad/CTF2 (33 kD) fragment, we found that the overexpression
of wild type PS-1 increases the formation of 105, 90, 79, 62 and 48 kD
E-cadherin fragments, whereas the dominant negative mutant of PS-1
did not. Furthermore, we found that treatment with γ-secretase inhib-
itor decreases the production of above E-cadherin fragments (105, 90,
79, 62, and 48 kD), except for a 29 kD fragment. Marambaud et al.
[44] showed that PS-1-mediated γ-secretase cleavage of E-cadherin
takes place between residues Leu731 and Arg732 at the membrane/
cytoplasm interface. However, we found that there are approximately
ﬁve PS-1 mediated γ-secretase cleavage sites in E-cadherin (Table 1
and Fig. 8). We cannot rule out the possibility that PS-1/γ-secretase
cleaves E-cadherin directly. However, given the fact that PS-1/γ-
Fig. 6. Effects of δ-catenin overexpression on prostate cancer cell expansion. (A) Rapid growth of tumor xenografts derived from Rv/δ cells. Tumor xenografts were generated after
s.c. injecting either Rv/C or Rv/δ cells into BALB/c nude mice, and tumor volumes were measured on the days indicated (n=4 for each).(B) Correlation between metastatic tumor
weight and 29 kD E-cadherin fragment. Metastatic tumors were formed around the neck of mice after tail-vein injection of Rv/δ cells. Upon analyzing these tumors for E-cadherin
status byWestern blot, larger tumors tended to have more processed E-cadherin fragments, especially 29 kD.(C) Increased β-catenin nuclear accumulation in xenografts tissue from
Rv/δ cells. Xenograft tissues were subjected to immunohistochemistry for β- and δ-catenin. In xenograft tumor tissues, those that were generated by injecting Rv/δ cells either sub-
cutaneously or intravenously showed clear and frequent nuclear β-catenin localization. Arrows indicate tumor cells displaying nuclear accumulation of β-catenin. Bar, 25 μm.
518 H. Kim et al. / Biochimica et Biophysica Acta 1822 (2012) 509–521secretase is a regulated intramembranous protease, it ismore likely that
other protease(s) activated by PS-1/γ-secretase are responsible for ac-
tual cleavage of E-cadherin in this case (Fig. 8).Fig. 7. Increased δ-catenin expression and E-cadherin processing in human prostate cancer
analyzed for E-cadherin status and δ-catenin expression. N, normal; T, Tumor. The arrow ind
quantiﬁed δ-catenin level in tumor and normal tissues and is normalized by correspondingThe existence of a direct interaction between PS-1 and E-cadherin
remains unresolved. For example, Baki et al. [45] showed that PS-1
binds cytoplasmic cadherin through its 604–615 CTF and inhibitsspecimens. Human prostate cancer tissues and matched adjacent normal tissues were
icates upper 75 kD E-cadherin band. The T/N ratio of δ-catenin levels was obtained from
quantiﬁed actin band.
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ﬁndings, favors a model whereby p120 and δ-catenin recruit PS-1/
γ-secretase complexes to E-cadherin. In other words, no direct inter-
action between PS-1 and E-cadherin can occur in the absence of p120
and δ-catenin. Recent reports demonstrated that p120 is a key com-
ponent of the cadherin–γ-secretase supercomplex [46], and that
p120 recruits cadherins to γ-secretase [47]. Our data show that the
δ-catenin mutant ΔC787 that cannot bind E-cadherin and PS-1 also
cannot induce E-cadherin processing or multi-layer growth. We also
recently found that deletion of either the N- or C-terminal sequences
outside the armadillo domains abolishes the tumor promoting effects
of δ-catenin [5]. Therefore, δ-catenin appears to require its full se-
quence for maintaining the ability to bind both E-cadherin and PS-1
in order to induce E-cadherin processing, which in turn mediates
multi-layer growth of the cell and increases tumor growth rates.
The 29 kD E-cadherin fragment is of considerable interest. Our
data show that this fragment was signiﬁcantly increased by both
MMP and γ-secretase inhibitor. Interestingly, the E-cadherin
fragments induced by Canadida albicans and Bacteroids fragilis toxin
are similar in size (35 and 33 kD, respectively), and were also induced
by a speciﬁc γ-secretase inhibitor. B. fragilis toxin stimulates cell pro-
liferation. The cleavage of E-cadherin induced by C. albicans and B.
fragilis toxin may destabilize the homotypic interaction between
adjacent cells andmay possibly contribute to a loss ofmonolayer integ-
rity [28,29]. It has been reported that the ADAM15-dependent genera-
tion of a soluble extracellular E-cadherin fragment activates HER2 as
well as proliferation and migration through the Erk pathway [26]. Re-
cently, Ferber et al. demonstrated that the cleaved cytoplasmic domain
of E-cadherin (E-cad/CTF2) can translocate to the nucleus and act as a
regulator of some transcription pathway, such as p120-Kaiso mediated
signaling [27]. Our data also show the nuclear immunostaining of
E-cadherin, and the presence of the 29 kD E-cadherin fragment in the
nuclear fractions of Rv/δ cells, and metastatic tumors containing
the 29 kD E-cadherin fragment tend to form larger tumors for which
the correlation coefﬁcient (R2 value) between the band intensity of
the 29 kD E-cadherin fragment and tumor weight is considerably
high. In this regard, it would be interesting to determine whether the
ectopic expression of 29 kD E-cadherin fragment promotes tumorigen-
esis. However, thus far, we do not know the identity of the protease(which is negatively regulated by MMP or γ-secretase) responsible
for the production of the 29 kD E-cadherin fragment.
Various coregulators for AR have been suggested to contribute to
the carcinogenesis of steroid-responsive prostate cancers [48].
β-Catenin is a known AR activator and AR ligand speciﬁcity determi-
nant. β-Catenin nuclear localization is frequently observed in various
types of tumors without exon 3 mutations, which suggests that
mechanisms other than APC/GSK-3β destruction complex may con-
tribute to the activation of this pathway [41,49]. Through the altered
expression of AR coactivators, prostate cancer cells may proliferate
regardless of serum androgen and transform into androgen-
independent prostate cancer [48]. From present studies, it appears
that δ-catenin can affect tumor progression by inducing E-cadherin
processing directly or, alternatively, can regulate the size of the
β-catenin pool. For the latter possibility, our data show that nuclear
β-catenin level is noticeably increased in Rv/δ cells and Rv/δ-derived
xenograft tumor tissue. Accordingly, LEF-1/β-catenin- and AR-
mediated transcriptional activities are remarkably increased. Zeng et
al. previously reported alteration of genes involved in cell cycle and
survival regulation in Rv/δ cells, especially upregulation of cyclin D1
and cdc34 [5]. Given the fact that δ-catenin immunoscore is prognos-
tically correlated with Gleason score [2] and that δ-catenin is also a
substrate for GSK-3 [50], it seems that δ-catenin overexpression to-
gether with E-cadherin processing consequently increases total and
nuclear β-catenin level. Thus, factors activating tumorigenic function
of δ-catenin described above will promote tumorigenesis of certain
cancers. In this regard, it is worth noting that apoptosis-resistant
LNCaP cells, which were generated by repeated exposure to apoptotic
stimuli, have more cytoplasmic/nuclear β-catenin and high TCF/LEF
transcriptional activity [51] since apoptotic stimuli is known to in-
duce E-cadherin processing. Indeed, full-length E-cadherin level is
decreased in apoptosis-resistant cells than those of parental cell,
though the status of E-cadherin processing cannot be veriﬁed as the
authors did not show the whole blot. On the other hand, modulation
of AR activity by growth factor, such as Her2/Neu/ErbB2, TGFβ,
Proline-rich tyrosine kinase 2(PYK2), IL-6, or IGF-I is of considerable
interest [48]. As δ-catenin mediated E-cadherin processing is depen-
dent on currently unidentiﬁed serum factors, it would be worth eluci-
dating whether such growth factors either from serum or cancer
520 H. Kim et al. / Biochimica et Biophysica Acta 1822 (2012) 509–521stromal cells are involved in the initiation of E-cadherin processing by
δ-catenin during prostate carcinogenesis.
The comparative effects of δ-catenin and p120 (the prototypic
member of the p120 protein family) on E-cadherin are of interest.
p120 and δ-catenin are known to be quite different in tumors in
one respect; that is, δ-catenin is overexpressed in some tumors,
including breast and prostate carcinoma, whereas p120 is underex-
pressed in some tumors, such as colon and lung carcinomas [2,52].
Moreover, tumors with lower p120 levels have low E-cadherin levels
and increased invasive and metastatic potential. Because different
cells express different p120 isoforms, the relative contributions
made by these isoforms (e.g., p120 1A vs. p120 3A) to tumor
progression require further investigation. It would be interesting to
compare the tumor growth rates and metastatic potentials of cells
differentially expressing p120 and δ-catenin. Furthermore, our recent
published data shows that p120 and δ-catenin compete with each
other to interact with E-cadherin [53]. Therefore, future investiga-
tions are required to determine whether E-cadherin processing and/
or endocytosis induced by p120 result in the same consequences as
those induced by δ-catenin. Regardless, we believe that our ﬁndings
explain in part how δ-catenin overexpression in some tumors affects
tumor proliferation and progression.
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